Advanced Therapies Week 2022 | The role of automation in manufacturing CAR T-cells
Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses advances in chimeric antigen receptor (CAR) T-cell therapy manufacturing, including developments in automation and shortened T-cell culture. Whilst a 24 hour manufacturing process has been in development, further research is required to assess feasibility. Dr Levine also describes T-Charge, a less labor-intensive novel CAR T-cell platform that expedites the culture time, requiring fewer reagents as a result. This interview took place at Advanced Therapies Week 2022.
Disclosures
Bruce Levine reports consultancy fees from Terumo, GSK; is part of the Scientific Advisory Board for Akron, Avectas, Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, and Vycellix; and is the Co-Founder and equity holder Tmunity Therapeutics, and Capstan Therapeutics. Conflict of interest is managed in accordance with University of Pennsylvania policy and oversight.
